Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 15/20 | 0.76 |
| ▸ | CYP1A1 | P04798 | 14/20 | 0.76 |
| ▸ | CYP1B1 | Q16678 | 14/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.61 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.61 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.61 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.61 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.61 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25706432 | 0.86 | CYP1A2 (1.00) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL3300283 | 0.85 | CYP1A2 (0.73) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL1547597 | 0.84 | CYP1A2 (0.73) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL2099078 | 0.84 | CYP1A2 (0.77) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL5324697 | 0.83 | CYP1A2 (0.65) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL9545111 | 0.83 | CYP1A2 (0.70) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL30411244 | 0.83 | CYP1A2 (0.70) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL96291 | 0.83 | ALDH1A1 (1.00) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL7003172 | 0.83 | CYP1A2 (0.70) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL11108516 | 0.83 | CYP1A2 (0.70) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 689 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492384-B2 | Imidazolylalkylcarbonyl derivatives as calcium channel modulators and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-07-23 | — | — | US | claimed |
| US-20090325979-A1 | NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-12-31 | — | — | US | claimed |
| EP-4397366-A2 | GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA | Ardelyx, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-12017989-B2 | Controlled release pharmaceutical formulations | UNITED THERAPEUTICS CORPORATION (US) | 2024-06-25 | — | — | US | disclosed |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-11963994-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| EP-3661945-B1 | GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA | ARDELYX INC (US) | 2024-04-03 | — | — | EP | disclosed |
| EP-4320132-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11883406-B2 | Method for producing alginic acid-folic acid conjugate, alginic acid-folic acid conjugate produced thereby and pharmaceutical composition containing the same | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2024-01-30 | — | — | US | disclosed |
| US-4795815-A | BACTERICIDES, MICROBIOCIDES | ELI LILLY AND COMPANY (US) | 1989-01-03 | — | — | US | disclosed |
| US-4767871-A | Pyrazolidinium ylides | ELI LILLY AND COMPANY (US) | 1988-08-30 | — | — | US | disclosed |
| US-4734504-A | 1-alkylated diazolidinones | ELI LILLY AND COMPANY (US) | 1988-03-29 | — | — | US | disclosed |
| US-4734505-A | 1-(alkylated)-2-(acylated)diazolidinones | ELI LILLY AND COMPANY (US) | 1988-03-29 | — | — | US | disclosed |
| US-4716232-A | 1-(vinyl phosphonate adduct) pyrazolidinones | ELI LILLY AND COMPANY (US) | 1987-12-29 | — | — | US | disclosed |
| EP-0203722-A1 | Bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0203723-A1 | 2,3-(dihydro)bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0202794-A1 | 7-Substituted-2,3-(Dihydro) bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-26 | — | — | EP | disclosed |
| EP-0202046-A1 | 7-Substituted bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12017989-B2 | Controlled release pharmaceutical formulations | PTGIR, PTGIS, PTGER1 | CYP1A2 333/4885CYP1A1 1126/4885CYP1B1 1041/4885 |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | REN, NHERF1, KCNJ11 | CYP1A2 1230/4885CYP1A1 1839/4885CYP1B1 2389/4885 |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | VIP, ARG1, CX3CR1 | CYP1A2 2774/4885CYP1A1 1382/4885CYP1B1 1694/4885 |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | SHH, GLI1, SMO | CYP1A2 4261/4885CYP1A1 3818/4885CYP1B1 2613/4885 |
| US-11963994-B2 | Inhibitors of IAP | BIRC5, XIAP, BIRC3 | CYP1A2 4785/4885CYP1A1 3962/4885CYP1B1 4528/4885 |
| US-20090325979-A1 | NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | CACNA1B, CACNA1C, ORAI1 | CYP1A2 3803/4885CYP1A1 3819/4885CYP1B1 3593/4885 |
| US-11883406-B2 | Method for producing alginic acid-folic acid conjugate, alginic acid-folic acid conjugate produced thereby and pharmaceutical composition containing the same | FOLR1, FOLR2, MTHFD1 | CYP1A2 2768/4885CYP1A1 3146/4885CYP1B1 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.